Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 6/20 | 0.97 |
| ▸ | KDR | P35968 | 7/20 | 0.80 |
| ▸ | RET | P07949 | 5/20 | 0.80 |
| ▸ | KIF5B | P33176 | 2/20 | 0.80 |
| ▸ | GAK | O14976 | 2/20 | 0.75 |
| ▸ | FLT1 | P17948 | 1/20 | 0.75 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.75 |
| ▸ | STK10 | O94804 | 1/20 | 0.75 |
| ▸ | FLT3 | P36888 | 1/20 | 0.75 |
| ▸ | JAK3 | P52333 | 1/20 | 0.75 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.75 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.75 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.75 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.75 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.75 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.75 |
| ▸ | SRC | P12931 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5570070 | 0.89 | EGFR (0.85) | EGFRABCG2CLK1LCKKDR | |
| SCHEMBL22590721 | 0.89 | EGFR (0.80) | EGFRABCG2CLK1LCKKDR | |
| SCHEMBL28635157 | 0.89 | EGFR (0.79) | EGFRABCG2CLK1LCKKDR | |
| SCHEMBL5565204 | 0.87 | KDR (0.79) | EGFRABCG2CLK1LCKKDR | |
| SCHEMBL5467825 | 0.87 | EGFR (1.00) | EGFRABCG2CLK1LCKKDR | |
| SCHEMBL5473778 | 0.87 | EGFR (0.80) | EGFRABCG2CLK1LCKKDR | |
| SCHEMBL5472599 | 0.87 | EGFR (1.00) | EGFRABCG2CLK1LCKKDR | |
| SCHEMBL3533221 | 0.87 | EGFR (0.80) | EGFRABCG2CLK1LCKKDR | |
| SCHEMBL1387156 | 0.86 | EGFR (0.75) | EGFRABCG2CLK1LCKKDR | |
| SCHEMBL2100447 | 0.86 | KDR (0.80) | EGFRABCG2CLK1LCKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | EGFR 1445/4885ABCG2 311/4885CLK1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.